efficaci
two
heat
cycl
sec
c
hr
c
use
manufactur
plasmaderiv
hepatitisb
vaccin
valid
inactiv
viru
famili
period
min
warm
c
alreadi
complet
inactiv
repres
nine
viru
famili
ie
poxviru
vaccinia
picornaviru
encephalomyocard
viru
togaviru
sindbi
viru
coronaviru
mous
hepat
viru
orthomyxoviru
influenza
viru
rhabdoviru
vesicular
stomat
viru
herp
viru
cytomegaloviru
lentiviru
human
immunodefici
viru
retroviru
murin
leukemia
viru
prolong
heat
c
heat
sec
c
parvoviru
canin
parvoviru
phage
also
complet
inactiv
papovaviru
repres
simian
viru
heatresist
viru
evalu
infect
reduc
tissu
cultur
infecti
dose
tcidso
per
ml
sec
c
margin
residu
activ
l
tcid
per
ml
observ
subsequ
pasteur
h
c
reduc
infect
studi
show
two
heatinactiv
step
use
product
vaccin
kill
wide
varieti
virus
might
present
human
blood
plasmaderiv
hepatitisb
vaccin
central
laboratori
netherland
red
cross
blood
transfus
servic
clb
inactiv
two
heat
cycl
sec
c
follow
hr
c
highli
efficaci
coutinho
et
al
desmyt
et
al
wong
et
al
safeti
vaccin
establish
chimpanze
reerinkbrong
et
al
reduct
least
chimpanzeeinfecti
dose
cid
hbv
manufactur
vaccin
observ
leli
et
al
sinc
introduct
vaccin
human
individu
immun
without
import
side
effect
procedur
use
manufactur
anoth
vaccin
merck
sharp
dohm
msd
effect
inactiv
hbv
tabor
et
al
eight
viru
group
gereti
tabor
urea
treatment
inactiv
rhabdoviru
poxviru
togaviru
herp
viru
coronaviru
reoviru
myxoviru
picornaviru
pepsin
treatment
kill
six
viru
group
complet
inactiv
picornaviru
repres
mengoviru
myxoviru
repres
newcastl
diseas
viru
effect
formalin
report
rather
modest
inactiv
human
immunodefici
viru
hiv
spire
et
al
contrast
effect
heat
liquid
environ
spire
et
al
martin
et
al
mcdougal
et
al
resnick
et
al
formalin
heat
inactiv
agent
nonanonb
hepat
tabor
gereti
yoshizawa
et
al
report
describ
efficaci
two
heat
step
appli
manufactur
hepatitisb
vaccin
clb
inactiv
viru
famili
sec
c
human
serum
protein
solut
ultracentrifug
resuspens
prepar
plasma
neg
hbsag
antihbc
antihb
accord
method
describ
purif
hepatitisb
vaccin
leli
et
al
inactiv
canin
parvoviru
cpv
simian
viru
ml
viru
stock
solut
ad
ml
human
serum
solut
contain
mg
protein
per
ml
mixtur
heat
close
bottl
sec
c
oil
bath
cool
ice
bath
solut
centrifug
hr
ooog
clarifi
supernat
steril
filter
temperatur
bottl
continu
monitor
datalog
apparatu
kay
instrument
sampl
taken
unheat
solut
heat
treatment
immedi
frozen
ethanolco
bath
h
c
human
protein
solut
heat
sec
c
heat
solut
clarifi
centrifug
ooog
steril
filter
inactiv
vaccinia
viru
sindbi
viru
encephalomyocard
viru
emc
mous
hepat
viru
mhv
influenza
viru
vesicular
stomat
viru
vsv
cytomegaloviru
cmv
hiv
murin
leukemia
viru
mulv
cpv
ml
stock
solut
dissolv
ml
protein
solut
contain
mg
protein
per
ml
mixtur
heat
c
water
bath
wherea
dummi
bottl
fill
protein
solut
temperatur
continu
monitor
warm
pasteur
c
thereaft
sever
sampl
taken
immedi
frozen
ethanolco
one
virusinactiv
experi
solut
heat
sec
c
use
directli
subsequ
pasteur
infect
titer
sequenti
sampl
viru
prepar
heat
inactiv
test
dilut
duplic
quadrupl
done
assess
percentag
cell
cultur
dilut
tabl
summar
virus
alreadi
inactiv
within
period
min
requir
reach
temperatur
c
although
infect
titer
variou
prepar
heat
vari
consider
residu
activ
observ
nine
viru
famili
min
requir
reach
c
tabl
show
heatresist
virus
inactiv
heat
c
prolong
heat
c
infect
cpv
reduc
tcid
per
ml
within
min
c
least
lo
tcid
per
ml
hr
c
sec
c
infect
alreadi
reduc
tcid
per
ml
min
heat
c
residu
activ
observ
heat
tcid
per
ml
hr
c
sec
c
reduct
tcid
per
ml
found
sec
heat
c
tcid
per
ml
margin
residu
activ
lo
tcid
per
ml
remain
unalt
subsequ
pasteur
hr
c
howev
protein
concentr
pasteur
residu
infect
higher
usual
protein
concentr
pasteur
vaccin
experi
show
vaccinia
viru
emc
sindbi
viru
mhv
influenza
viru
vsv
cmv
hiv
mulv
evid
highli
sensit
heat
treatment
viral
infect
recov
min
requir
reach
temperatur
c
least
tcid
per
ml
cpv
tcid
per
ml
phage
phix
complet
inactiv
prolong
pasteur
c
sec
heat
oc
infect
reduc
tcid
per
ml
sec
c
margin
residu
infect
l
tcid
per
ml
elimin
subsequ
pasteur
experi
protein
concentr
pasteur
higher
regular
product
vaccin
inactiv
final
heat
step
may
underestim
consequ
high
concentr
protect
protein
similar
result
report
rohwer
found
heatresist
subpopul
phage
x
c
presenc
brain
homogen
studi
confirm
result
investig
also
establish
hiv
effect
kill
liquid
environ
spire
et
al
martin
et
al
mcdougal
et
al
resnick
et
al
repres
group
slow
virus
includ
studi
rohwer
report
heatresist
scrapi
agent
destroy
within
min
exposur
c
aqueou
solut
absenc
extran
infecti
agent
start
plasma
lot
vaccin
confirm
accord
requir
world
health
organ
henc
highli
unlik
batch
vaccin
pass
test
contain
residu
infect
viru
purif
inactiv
step
use
